FDA Biosimilar Interchangability Regulations Completed

Started by lord999
This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

lord999

Full Member
Moderator Emeritus
Lifetime Donor
20+ Year Member
Advertisement - Members don't see this ad


That's going to be very interesting for BIO. I wouldn't suggest dumping your Amgen or Genentech yet, but the biologics market is going to be interesting in about five to seven years from now.
 
Developing biosimilars for biologics seems like a daunting task since most all of them are monoclonal antibodies.